-
公开(公告)号:US20130204209A1
公开(公告)日:2013-08-08
申请号:US13831695
申请日:2013-03-15
申请人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela Macfarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
发明人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela Macfarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
IPC分类号: A61F9/00
CPC分类号: G01N33/558 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K31/57 , A61K31/573 , A61K31/58 , A61K38/385 , A61K47/32 , A61K47/34 , A61K47/38 , A61K2039/505 , C07K16/22 , C07K2317/24 , C07K2317/55 , Y10T29/49826
摘要: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.
-
公开(公告)号:US20100255061A1
公开(公告)日:2010-10-07
申请号:US12696678
申请日:2010-01-29
申请人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela MacFarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
发明人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela MacFarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
IPC分类号: A61F9/00 , A61K39/395 , A61P27/02 , A61K31/5575 , A61K31/58 , A61F2/14 , B23P17/04
CPC分类号: G01N33/558 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K31/57 , A61K31/573 , A61K31/58 , A61K38/385 , A61K47/32 , A61K47/34 , A61K47/38 , A61K2039/505 , C07K16/22 , C07K2317/24 , C07K2317/55 , Y10T29/49826
摘要: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小,当耦合到多孔结构并且植入患者体内时,释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 多个互连通道可以从第一侧延伸到第二侧,以便将第一侧上的第一多个开口与第二侧上的第二多个开口连接。 第一侧的每个开口可以与多个互连通道连接到第二侧的每个开口,使得当一个或多个开口被阻塞时可以基本上保持治疗剂的释放速度 ,例如当器件长时间植入时,可以使用颗粒,细胞,细菌或组织。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置许多包括可扩张的保留结构和可扩张的储存器,使得该装置可以从输送装置的内腔输送,并且在定位在患者体内时膨胀。 治疗装置可以包括当植入患者时将治疗剂注入装置中的可穿透屏障。
-
公开(公告)号:US08399006B2
公开(公告)日:2013-03-19
申请号:US12696678
申请日:2010-01-29
申请人: Eugene de Juan, Jr. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela Macfarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
发明人: Eugene de Juan, Jr. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , Hanson S. Gifford, III , K. Angela Macfarlane , Cary J. Reich , Michael Barrett , Randolph E. Campbell , Robert George , Douglas Sutton
CPC分类号: G01N33/558 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K31/57 , A61K31/573 , A61K31/58 , A61K38/385 , A61K47/32 , A61K47/34 , A61K47/38 , A61K2039/505 , C07K16/22 , C07K2317/24 , C07K2317/55 , Y10T29/49826
摘要: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.
摘要翻译: 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小,当耦合到多孔结构并且植入患者体内时,释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 多个互连通道可以从第一侧延伸到第二侧,以便将第一侧上的第一多个开口与第二侧上的第二多个开口连接。 第一侧的每个开口可以与多个互连通道连接到第二侧的每个开口,使得当一个或多个开口被阻塞时可以基本上保持治疗剂的释放速度 ,例如当器件长时间植入时,可以使用颗粒,细胞,细菌或组织。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置许多包括可扩张的保留结构和可扩张的储存器,使得该装置可以从输送装置的内腔输送,并且在定位在患者体内时膨胀。 治疗装置可以包括当植入患者时将治疗剂注入装置中的可穿透屏障。
-
公开(公告)号:US20140031769A1
公开(公告)日:2014-01-30
申请号:US13988298
申请日:2011-11-18
申请人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
发明人: Eugene de Juan, JR. , Yair Alster , Steven M. Chamow , Kathleen Cogan Farinas , K. Angela MacFarlane , Cary J. Reich , Randolph E. Campbell , Signe Erickson , Blaine Bueche
IPC分类号: A61F9/00
CPC分类号: A61F9/0017 , A61K9/0051 , A61K9/1647 , A61K9/1652 , A61K31/573
摘要: An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.
摘要翻译: 治疗剂的可注射制剂可以包含治疗剂和稳定剂,使得当治疗剂从治疗装置释放时,大部分稳定剂保留在治疗装置中以稳定治疗剂。 可注射制剂可以包含一种或多种粘合剂颗粒或可侵蚀材料颗粒,使得可以将制剂注射到治疗装置中。 结合剂颗粒可以可逆地结合治疗剂以调节治疗剂的释放,并且可侵蚀的材料颗粒可以产生酸的质子,以增加治疗剂的稳定性并且可以调节治疗剂的释放。 治疗剂可以与稳定剂,结合剂颗粒或可侵蚀颗粒中的一种或多种组合以增加治疗剂的稳定性并且可以调节释放。
-
公开(公告)号:US20140248296A1
公开(公告)日:2014-09-04
申请号:US13968264
申请日:2013-08-15
IPC分类号: A61K47/48 , A61K47/36 , A61K38/17 , A61K39/395
CPC分类号: A61K47/645 , A61K38/00 , C07K16/22 , C07K2317/24 , C07K2317/76 , C07K2319/30
摘要: A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.
摘要翻译: 公开了包含与治疗化合物偶联的带电部分的药物组合物。 带电部分被配置为与生物组织中的相反电荷的至少一种类型的组分相互作用以产生用于延长药物递送的原位贮库。 生物组织可以是眼组织或含有带电组分的任何组织。
-
公开(公告)号:US20110282093A1
公开(公告)日:2011-11-17
申请号:US12742423
申请日:2008-11-12
IPC分类号: C07C317/08
CPC分类号: A61K31/513 , C08G65/3322 , C08G65/33306 , C08G65/33337 , C08G65/33389 , C08G65/3346 , C08G65/337
摘要: The invention relates to heterobifunctional polyethylene glycol reagents, methods of producing them and methods of using them.
摘要翻译: 本发明涉及异双功能聚乙二醇试剂,其制备方法和使用它们的方法。
-
公开(公告)号:US5329028A
公开(公告)日:1994-07-12
申请号:US926077
申请日:1992-08-05
IPC分类号: C07D207/44 , C07D207/452 , C07K1/107 , C07K14/805
CPC分类号: C07D207/452 , C07K1/1072 , C07K14/805 , Y10S435/96 , Y10S435/974 , Y10S436/829 , Y10S530/812
摘要: The invention is from the field of heterobifunctional cross-linking reagents. More particularly, the invention concerns cross-linking reagents which combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, thereby allowing coupling of aldehydes to free thiols.
摘要翻译: 本发明是来自异双功能交联剂的领域。 更具体地说,本发明涉及将亲核酰肼残基与亲电马来酰亚胺残基相结合的交联试剂,从而使醛与游离硫醇结合。
-
公开(公告)号:US5929211A
公开(公告)日:1999-07-27
申请号:US923590
申请日:1997-09-04
IPC分类号: C07D207/44 , C07D207/452 , C07K1/107 , C07K14/805 , C07K15/14
CPC分类号: C07D207/452 , C07K1/1072 , C07K14/805 , Y10S435/96 , Y10S435/974 , Y10S436/829 , Y10S530/812
摘要: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.
-
公开(公告)号:US5889155A
公开(公告)日:1999-03-30
申请号:US415018
申请日:1995-03-31
IPC分类号: C07D207/44 , C07D207/452 , C07K1/107 , C07K14/805 , C07K15/14
CPC分类号: C07D207/452 , C07K1/1072 , C07K14/805 , Y10S435/96 , Y10S435/974 , Y10S436/829 , Y10S530/812
摘要: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.
-
公开(公告)号:US5605791A
公开(公告)日:1997-02-25
申请号:US416402
申请日:1995-03-31
IPC分类号: C07D207/44 , C07D207/452 , C07K1/107 , C07K14/805 , C12Q1/68 , C12Q1/70 , G01N33/53
CPC分类号: C07D207/452 , C07K1/1072 , C07K14/805 , Y10S435/96 , Y10S435/974 , Y10S436/829 , Y10S530/812
摘要: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.
摘要翻译: 本发明提供异双功能交联试剂和使用交联试剂的方法。 本发明的交联试剂将亲核酰肼残基与亲电马来酰亚胺残基相结合,使醛与游离硫醇偶联。 在本发明的方法中,可以使用包含通过公开的交联试剂缀合到可检测标记的CD4分子的缀合物来检测人免疫缺陷病毒(HIV)感染的细胞。
-
-
-
-
-
-
-
-
-